MIP immunotherapy alongside multidrug therapy speeds clearance in multibacillary leprosy

Design

systematic review and meta-analysis of four randomised and three non-randomised trials, published 1980-2023, RoB2 and ROBINS-I appraisal

Population

patients with multibacillary and paucibacillary leprosy receiving standard multidrug therapy with or without MIP vaccine

Primary outcome

change in clinical score and bacterial index at 12 and 24 months

Effect

clinical score mean difference -1.35 (95% CI -2.12 to -0.57) at 12 months and -2.62 (95% CI -4.28 to -0.96) at 24 months in randomised trials

India accounts for around 52% of the world's new leprosy cases, which makes this synthesis more directly relevant to Indian practice than almost anything else on the desk today. The review pooled four randomised and three non-randomised trials of Mycobacterium indicus pranii vaccine — formerly Mw, developed in India — given alongside standard multidrug therapy, with bias assessed using RoB2 and ROBINS-I.

Across the randomised trials, clinical scores fell further with added MIP than with chemotherapy alone: mean difference -1.35 (95% CI -2.12 to -0.57) at 12 months and -2.62 (95% CI -4.28 to -0.96) at 24 months. The non-randomised studies showed larger effects — -2.97 and -3.10 at the same time points — which is the expected direction for weaker designs and a reason to anchor on the randomised estimates. Subgroup analysis put the benefit in borderline lepromatous and lepromatous disease, for both clinical score and bacterial index. The vaccine was reported safe and well tolerated.

Two cautions belong with the recommendation. The included trials span 1980 to 2023, so some predate current multidrug regimens, and a clinical score is a composite of signs rather than a patient-reported or disability outcome — faster bacterial clearance is a good surrogate for cure, not a demonstration that fewer patients end up with nerve damage or deformity. What this changes is the standing of adjunct immunotherapy in high-bacillary-load disease: it moves from a locally-favoured practice to one with pooled randomised support, and is worth raising with your leprosy programme for BL and LL patients specifically.

• Consider adjunct MIP immunotherapy specifically in borderline lepromatous and lepromatous disease, where the subgroup benefit sat
• Do not substitute it for multidrug therapy — every trial gave it alongside standard chemotherapy
• Anchor expectations on the randomised estimates, not the larger non-randomised ones
• Continue routine nerve function assessment; faster bacterial clearance was not shown to reduce disability
• Raise availability and supply with your state leprosy programme before offering it — the vaccine is Indian-developed and access is programme-dependent

The statistics, in plain English

A mean difference of -2.62 with an interval from -4.28 to -0.96 excludes zero, so a real improvement in clinical score is likely — but the interval is wide, and a clinical score point is not self-explanatory to a reader who does not use that scale daily, so the size of the benefit matters less than its direction and consistency. The non-randomised studies produced estimates roughly twice as large, the classic signature of confounding by indication. Pooling only four randomised trials means heterogeneity is poorly estimated and a single influential study could be driving much of the result.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.